肾病综合征的长期结局:依据肾活检诊断与蛋白尿分层
遗传性肾病综合征10年肾脏存活率仅29%,FSGS为58%,微小病变为87%;早期蛋白尿控制与更低肾衰竭风险相关,FSGS中蛋白尿<1.5 g/g者10年肾脏存活率达90%。
要点
- 遗传性肾病综合征进展快,10年肾脏存活率仅29%,现有治疗反应差。
- FSGS患者10年肾脏存活率58%,蛋白尿控制程度与预后强烈相关。
- 微小病变10年肾脏存活率87%,各蛋白尿水平下预后均优于FSGS。
核心结论
- 遗传性肾病综合征肾脏结局差,FSGS结局与蛋白尿水平强烈相关,微小病变蛋白尿控制更好且各水平下结局更优。
研究设计与样本
- 生存分析索引日期为疾病发病日期,中位随访8.2年(四分位距4.3–13.1年)。
主要发现
- 30%患者达到肾衰竭或死亡;1303例FSGS,1153例微小病变,105例遗传性肾病综合征。
- 10年肾脏存活概率(95%CI):遗传性29%(20–38),FSGS 58%(55–61),微小病变87%(85–89)。
- 平均(SD)eGFR年下降率:遗传性−26.5(34.7),FSGS −6.2(14.3),微小病变−1.9(10.2)ml/min per 1.73 m2。
- FSGS发病6–12个月最低蛋白尿值对应10年肾脏存活率(95%CI):完全缓解(<0.3 g/g)88%(70–96),部分缓解(0.3–3.5 g/g)65%(50–76),未缓解(>3.5 g/g)37%(26–48)。
- FSGS发病6–24个月时间平均蛋白尿<1.5 g/g与10年肾脏存活率90%相关;微小病变6–12个月最低蛋白尿完全缓解者10年肾脏存活率89%(79–94),部分缓解75%(51–89),未缓解64%(41–81)。
关键数值与推荐
- FSGS发病6–24个月时间平均蛋白尿<1.5 g/g与90%的10年肾脏存活率相关。
- FSGS发病6–12个月最低蛋白尿完全缓解(<0.3 g/g)者10年肾脏存活率88%(95%CI 70–96)。
- 微小病变发病6–12个月最低蛋白尿完全缓解者10年肾脏存活率89%(95%CI 79–94)。
临床怎么用
- 肾活检诊断可分层预测肾病综合征长期肾衰竭风险,遗传性者风险最高。
- FSGS和微小病变应尽早控制蛋白尿,FSGS中蛋白尿<1.5 g/g与良好10年肾脏结局相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In nephrotic syndrome, diagnosis was associated with kidney failure risk: very high in monogenic cases, substantial in FSGS, and less but not zero in minimal change disease. Early control of proteinuria was associated with lower kidney failure risk, and in FSGS levels <1.5 g/g are associated with good kidney outcomes at 10 years. Monogenic nephrotic syndrome cases had very high proteinuria and rapid progression to kidney failure with little response to current treatments. BACKGROUND: The UK National Registry of Rare Kidney Diseases Idiopathic Nephrotic Syndrome cohort includes adults and children with genetic nephrotic syndrome, FSGS, and minimal change disease. This study examines long-term patient outcomes as a function of kidney biopsy diagnosis and proteinuria control. METHODS: Two thousand four hundred and sixty-seven adults and 1599 children were followed to establish outcomes including eGFR slope and kidney survival by diagnosis, analyzed as a function of proteinuria from disease onset for FSGS and minimal change disease. Enrollment began in 2010, with follow-up to September 2023. Index date for the survival analyses was date of disease onset. RESULTS: The cohort had a median (interquartile range) follow-up of 8.2 (4.3–13.1) years; 30% of patients reached kidney failure or died. In total, 1303 patients had FSGS, 1153 had minimal change disease, and 105 had monogenic nephrotic syndrome. Children showed relatively preserved mean kidney function at disease onset (eGFR >100 ml/min per 1.73 m2), compared with adults (FSGS 61 ml/min per 1.73 m2; minimal change disease 76 ml/min per 1.73 m2). Kidney survival probability (95% confidence interval [CI]) at 10 years varied with diagnosis: genetic 29% (20 to 38), FSGS 58% (55 to 61), minimal change disease 87% (85 to 89) with mean (SD) rates of eGFR loss −26.5 (34.7), −6.2 (14.3), and −1.9 (10.2) ml/min per 1.73 m2 per year, respectively. FSGS 10-year kidney survival (95% CI) for 6–12 months lowest proteinuria value in complete remission (<0.3 g/g), partial remission (0.3–3.5 g/g), and no remission (>3.5 g/g) was 88% (70 to 96), 65% (50 to 76), and 37% (26 to 48), respectively. Time-averaged proteinuria of <1.5 g/g over 6–24 months from disease onset was associated with 90% 10-year kidney survival. For minimal change disease, patients' 10-year kidney survival (95% CI) stratified by 6–12 months lowest proteinuria value was complete remission 89% (79 to 94), partial remission 75% (51 to 89), and no remission 64% (41 to 81). In FSGS and minimal change disease, 10-year eGFR slope was strongly correlated with absolute levels of proteinuria. CONCLUSIONS: Kidney outcomes were poor in genetic nephrotic syndrome; in FSGS, outcomes were strongly associated with the proteinuria level. Patients with minimal change disease had better proteinuria control than FSGS and had better outcomes at each proteinuria level.
引用
- Pitcher D, Braddon F, Hendry B, et al. Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria. J Am Soc Nephrol. 2025. PMID: 40244693. doi:10.1681/ASN.0000000610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。